300 related articles for article (PubMed ID: 25827132)
1. Targeting the immune system to treat lung cancer: rationale and clinical experience.
Guibert N; Delaunay M; Mazières J
Ther Adv Respir Dis; 2015 Jun; 9(3):105-20. PubMed ID: 25827132
[TBL] [Abstract][Full Text] [Related]
2. Current Perspectives in Immunotherapy for Non-Small Cell Lung Cancer.
Garon EB
Semin Oncol; 2015 Oct; 42 Suppl 2():S11-8. PubMed ID: 26477470
[TBL] [Abstract][Full Text] [Related]
3. Immune checkpoint inhibitors in lung cancer: past, present and future.
Seetharamu N; Budman DR; Sullivan KM
Future Oncol; 2016 May; 12(9):1151-63. PubMed ID: 27019997
[TBL] [Abstract][Full Text] [Related]
4. Emerging immunotherapies in the treatment of non-small cell lung cancer (NSCLC): the role of immune checkpoint inhibitors.
Langer CJ
Am J Clin Oncol; 2015 Aug; 38(4):422-30. PubMed ID: 24685885
[TBL] [Abstract][Full Text] [Related]
5. Targeting the immune system in the treatment of non-small-cell lung cancer.
Rangachari D; Brahmer JR
Curr Treat Options Oncol; 2013 Dec; 14(4):580-94. PubMed ID: 23934510
[TBL] [Abstract][Full Text] [Related]
6. [Immune alterations in lung cancer - the new therapeutic approach].
Domagała-Kulawik J; Osińska I
Pneumonol Alergol Pol; 2014; 82(3):286-99. PubMed ID: 24793154
[TBL] [Abstract][Full Text] [Related]
7. Immune checkpoint therapy for non-small-cell lung cancer: an update.
Xia B; Herbst RS
Immunotherapy; 2016; 8(3):279-98. PubMed ID: 26860624
[TBL] [Abstract][Full Text] [Related]
8. Immunotherapy for lung cancer: ongoing clinical trials.
Declerck S; Vansteenkiste J
Future Oncol; 2014 Jan; 10(1):91-105. PubMed ID: 24143916
[TBL] [Abstract][Full Text] [Related]
9. Optimal management of immune-related toxicities associated with checkpoint inhibitors in lung cancer.
Howell M; Lee R; Bowyer S; Fusi A; Lorigan P
Lung Cancer; 2015 May; 88(2):117-23. PubMed ID: 25776466
[TBL] [Abstract][Full Text] [Related]
10. Immunotherapy and lung cancer: current developments and novel targeted therapies.
Domingues D; Turner A; Silva MD; Marques DS; Mellidez JC; Wannesson L; Mountzios G; de Mello RA
Immunotherapy; 2014; 6(11):1221-35. PubMed ID: 25496336
[TBL] [Abstract][Full Text] [Related]
11. Rationale for chemotherapy, immunotherapy, and checkpoint blockade in SCLC: beyond traditional treatment approaches.
Spigel DR; Socinski MA
J Thorac Oncol; 2013 May; 8(5):587-98. PubMed ID: 23546044
[TBL] [Abstract][Full Text] [Related]
12. Checkpoint blocking antibodies in cancer immunotherapy.
Kyi C; Postow MA
FEBS Lett; 2014 Jan; 588(2):368-76. PubMed ID: 24161671
[TBL] [Abstract][Full Text] [Related]
13. Enhancement of antitumor immunity by combining anti-cytotoxic T lymphocyte antigen-4 antibodies and cryotreated tumor lysate-pulsed dendritic cells in murine osteosarcoma.
Kawano M; Itonaga I; Iwasaki T; Tsumura H
Oncol Rep; 2013 Mar; 29(3):1001-6. PubMed ID: 23291864
[TBL] [Abstract][Full Text] [Related]
14. Promising immunotherapies for esophageal cancer.
Tanaka T; Nakamura J; Noshiro H
Expert Opin Biol Ther; 2017 Jun; 17(6):723-733. PubMed ID: 28366014
[TBL] [Abstract][Full Text] [Related]
15. The perspective of immunotherapy: new molecules and new mechanisms of action in immune modulation.
Blank CU
Curr Opin Oncol; 2014 Mar; 26(2):204-14. PubMed ID: 24424272
[TBL] [Abstract][Full Text] [Related]
16. Role of immunotherapy in the treatment of advanced non-small-cell lung cancer.
Rijavec E; Genova C; Alama A; Barletta G; Sini C; Pronzato P; Coco S; Dal Bello MG; Savarino G; Truini A; Boccardo F; Grossi F
Future Oncol; 2014 Jan; 10(1):79-90. PubMed ID: 24328411
[TBL] [Abstract][Full Text] [Related]
17. Beyond the standard of care: a review of novel immunotherapy trials for the treatment of lung cancer.
Hall RD; Gray JE; Chiappori AA
Cancer Control; 2013 Jan; 20(1):22-31. PubMed ID: 23302904
[TBL] [Abstract][Full Text] [Related]
18. Human vaccines & immunotherapeutics: news.
Riedmann EM
Hum Vaccin Immunother; 2013 Jul; 9(7):1395-8. PubMed ID: 23863285
[TBL] [Abstract][Full Text] [Related]
19. [Progress in Immunotherapy for Squamous Non-small Cell Lung Cancer].
Wang S; Li J
Zhongguo Fei Ai Za Zhi; 2016 Oct; 19(10):682-686. PubMed ID: 27760599
[TBL] [Abstract][Full Text] [Related]
20. Failure of cancer vaccines: the significant limitations of this approach to immunotherapy.
Bodey B; Bodey B; Siegel SE; Kaiser HE
Anticancer Res; 2000; 20(4):2665-76. PubMed ID: 10953341
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
